Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Stopped early · Phase 1
Conditions studied: Multiple Myeloma
In brief
This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
Key facts
- Study ID
- NCT05289492
- Run by
- iTeos Therapeutics
- People needed
- 16
- Starts
- 2022-05-01
- Expected to finish
- 2023-11-29
- Last updated by the study team
- 2024-10-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All participants must have a documented diagnosis of relapse/refractory Multiple Myeloma and have measurable disease as defined per IMWG criteria.
- All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).
- All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.
- All participants must have adequate organ function.
- Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.
You may not qualify if…
- All participants with non-secretory MM
- All participants with known auto-immune disease
- All participants with history of life-threatening toxicity related to prior immune therapy.
- All participants with active graft versus host disease after allogeneic stem cell transplantation.
- All participants with active, unstable cardiovascular function.
- All participants with active infection requiring systemic therapy.
- All participants with hypersensitivity to any of the treatments.
- All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.
Where it is running
- Banner MD Anderson — Gilbert, Arizona, United States
- Eastern Connecticut Hematology & Oncology — Norwich, Connecticut, United States
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- Fred Hutchinson Cancer Center — Seattle, Washington, United States
- ZNA Cadix — Antwerp, Belgium
- Institut Jules Bordet — Brussels, Belgium
- Universitaire Ziekenhuizen KU Leuven — Leuven, Belgium
- CHU Amiens — Amiens, France
- Centre Hospitalier Universitaire de Nantes — Nantes, France
- APHP Hôpital Saint-Antoine — Paris, France
- CHU de Poitiers — Poitiers, France
- CHU Toulouse — Toulouse, France
- Hospital Fundacion Jimenez Diaz — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.